Ticker

Rallybio Corporation (NASDAQ: RLYB - Get Free Report) was the target of a significant decrease in short interest during the month of February. As of February 13th, there was short interest totaling 38,974 shares, a decrease of 72.5% from the January 29th total of 141,643 shares. Currently, 0.8% of the shares of the company are short

Complement-mediated diseases arise from overactivation or dysfunction of the complement system, a part of the innate immune system.

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced positive results from its Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) clinical trial evaluating RLYB116, the Company's innovative, once-weekly, small volume,…

Here is a look at why companies split their stocks and why it matters. Upcoming splits worth keeping an eye on include one by Southern Copper..

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) will effect a one-for-eight reverse stock split of its issued and outstanding common stock. Stockholders of Rallybio approved an amendment to Rallybio's Amended and Restated Certificate of Incorporation (the “Amendment”) to effect the reverse stock split at a Special Meeting of Stockholders held on January 26, 2026. The reverse stock split is…